A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.

开始日期2024-12-12

申办/合作机构

上海细胞治疗集团股份有限公司

NCT06446128

/ Active, not recruiting早期临床1期

A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

开始日期2024-04-01

申办/合作机构

上海细胞治疗集团股份有限公司

NCT06327997

/ Recruiting早期临床1期

Exploratory Study on the Treatment of Advanced Solid Tumor With Non-viral Vector Multi-targeted Autosecretory Multifunctional Antibody CAR-T Cell Injection

The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were infused on day 0 (the dose was determined according to the requirements of climbing/expansion). The safety intensive observation period was 28 days after infusion, and the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation and evaluation were carried out according to the follow-up visit point, and the follow-up period was 1 year. From the second year, the telephone follow-up period was entered.

开始日期2024-03-07

申办/合作机构

上海细胞治疗集团股份有限公司

100 项与上海细胞治疗集团股份有限公司相关的临床结果

登录后查看更多信息

0 项与上海细胞治疗集团股份有限公司相关的专利（医药）

登录后查看更多信息

项与上海细胞治疗集团股份有限公司相关的文献（医药）

2025-01-01·DRUG DISCOVERY TODAY

Targeting spleen tyrosine kinase (SYK): structure, mechanisms and drug discovery

Review

作者: Lu, Yingying ; Wang, Lilin ; Zhang, Lan ; Zhang, Tongtong ; Guo, Chuanxin ; Zhang, Shuangqian

Spleen tyrosine kinase (SYK) is a crucial non-receptor tyrosine kinase involved in signaling pathways that regulate various cellular processes. It is primarily expressed in hematopoietic cells and myeloid cells, which are crucial for B-cell development, maturation and antibody production, and it is a key therapeutic target for autoimmune and allergic diseases. Overexpression of SYK is also associated with cancer and cardiovascular, cerebrovascular and neurodegenerative diseases, contributing to their initiation and progression. SYK is a promising target for drug development, and several inhibitors have already been reported. This review covers the structure and regulatory pathways of SYK, as well as its links to various diseases. It also highlights key small-molecule SYK inhibitors, their design strategies and their potential therapeutic benefits, aiming to enhance our understanding and aid in the discovery of more-effective SYK inhibitors.

2024-10-01·DRUG DISCOVERY TODAY

Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy

Review

作者: Li, Zixiang ; Zhang, Lan ; Wang, Huiping ; Fu, Leilei ; Jin, Wenke ; Guo, Chuanxin

Eukaryotic elongation factor 2 kinase (eEF2K) is a member of the α-kinase family that is activated by calcium/calmodulin. Of note, eEF2K is crucial for regulating translation and is often highly overexpressed in malignant cells. Therefore in this review, we summarize the molecular structure of eEF2K and its oncogenic roles in cancer. Moreover, we further discuss the inhibition of eEF2K with small-molecule inhibitors and other new emerging therapeutic strategies in cancer therapy. Taken together, these inspiring findings provide new insights into a promising strategy for inhibiting eEF2K to greatly improve future cancer therapy.

2024-07-12·ONCOGENE

Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4

Article

作者: Yu, Jing ; Fang, Yuan ; Li, Jiaguo ; Lv, Zhenzhen ; Zeng, Jianyao ; Tian, Zhidan ; Xu, Wenfeng ; Liu, Tao ; Huang, Qian ; Zhang, Zixuan ; Qian, Qijun ; Wang, Xiaodie ; Zhu, Weimin

Abstract:

The combination of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies has potential for enhancing clinical efficacy. We described the development and antitumor activity of Z15-0, a bispecific nanobody targeting both the PD-1 and CTLA-4 pathways simultaneously. We designed and optimized the mRNA sequence encoding Z15-0, referred to as Z15-0-2 and through a series of in vitro and in vivo experiments, we established that the optimized Z15-0-2 mRNA sequence significantly increased the expression of the bispecific nanobody. Administration of Z15-0-2 mRNA to tumor-bearing mice led to greater inhibition of tumor growth compared to controls. In aggregate, we introduced a novel bispecific nanobody and have re-engineered it to boost expression of mRNA, representing a new drug development paradigm.

366

项与上海细胞治疗集团股份有限公司相关的新闻（医药）

2025-04-01

·微信

复星医药净利润回归正增长，吴以芳：相信CAR-T产品会被纳入丙类目录

财报免疫疗法生物类似药细胞疗法

2025-03-28

·同写意

中国澳门上市，CAR-T疗法的破局者

细胞疗法上市批准优先审批免疫疗法ASH会议

2025-03-28

·同写意

厚积薄发！乐普生物现金收支基本打平

引进/卖出优先审批临床3期免疫疗法财报

100 项与上海细胞治疗集团股份有限公司相关的药物交易

登录后查看更多信息

100 项与上海细胞治疗集团股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年04月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

自分泌PD1抗体靶向间皮素嵌合抗原受体T细胞（上海细胞治疗集团） ( MSLN x PD-1 )	间皮瘤更多	临床1/2期
PD-1 antibody CD19-CAR T therapy ( CD19 x PD-1 )	B细胞淋巴瘤更多	临床1/2期
DC cells(Shanghai Cell Therapy Group) ( CTLA4 x PD-1 )	实体瘤更多	临床1期
BZE-2204 ( BCMA x CD19 x CD22 )	难治性B细胞淋巴瘤更多	早期临床1期
BaizeDC ( CTLA4 x PD-1 x p53 x survivin )	实体瘤更多	早期临床1期